Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 277

1.

Utility of immunohistochemistry in the evaluation of necrotic thyroid tumors.

Judkins AR, Roberts SA, Livolsi VA.

Hum Pathol. 1999 Nov;30(11):1373-6.

PMID:
10571520
2.

Sensitivity and specificity of antibodies on necrotic tumor tissue.

Judkins AR, Montone KT, LiVolsi VA, van de Rijn M.

Am J Clin Pathol. 1998 Nov;110(5):641-6.

PMID:
9802350
3.
4.

Retinoblastoma expression in thyroid neoplasms.

Anwar F, Emond MJ, Schmidt RA, Hwang HC, Bronner MP.

Mod Pathol. 2000 May;13(5):562-9.

5.
6.

Does Hurthle cell lesion/neoplasm predict malignancy more than follicular lesion/neoplasm on thyroid fine-needle aspiration?

Pu RT, Yang J, Wasserman PG, Bhuiya T, Griffith KA, Michael CW.

Diagn Cytopathol. 2006 May;34(5):330-4.

7.

Thyroid transcription factor-1, thyroglobulin, cytokeratin 7, and cytokeratin 20 in thyroid neoplasms.

Bejarano PA, Nikiforov YE, Swenson ES, Biddinger PW.

Appl Immunohistochem Mol Morphol. 2000 Sep;8(3):189-94.

PMID:
10981870
8.

Fine-needle aspiration biopsy of papillary thyroid carcinoma: diagnostic utility of cytokeratin 19 immunostaining.

Nasser SM, Pitman MB, Pilch BZ, Faquin WC.

Cancer. 2000 Oct 25;90(5):307-11.

PMID:
11038428
9.
10.
11.

Diagnosis of necrotic and degenerate thyroid lesions: value of immunohistochemistry.

Chai SM, Kumarasinghe MP.

Histopathology. 2011 Sep;59(3):496-503. doi: 10.1111/j.1365-2559.2011.03961.x.

PMID:
22034889
12.

Immunohistochemical analysis of thyroid adenomas with Hurthle cells.

Kanthan R, Radhi JM.

Pathology. 1998 Feb;30(1):4-6.

PMID:
9534199
13.

Galectin-3, fibronectin-1, CITED-1, HBME1 and cytokeratin-19 immunohistochemistry is useful for the differential diagnosis of thyroid tumors.

Prasad ML, Pellegata NS, Huang Y, Nagaraja HN, de la Chapelle A, Kloos RT.

Mod Pathol. 2005 Jan;18(1):48-57.

14.

[Thyroidal oxyphilic tumors].

Sabo R, Zohar Y, Schwartz A, Segal K.

Harefuah. 1994 Feb 15;126(4):183-6, 240. Hebrew.

PMID:
8168757
15.

CA125 and thyroglobulin staining in papillary carcinomas of thyroid and ovarian origin is not completely specific for site of origin.

Keen CE, Szakacs S, Okon E, Rubin JS, Bryant BM.

Histopathology. 1999 Feb;34(2):113-7.

PMID:
10064389
16.

Keratin subsets in papillary and follicular thyroid lesions. A paraffin section analysis with diagnostic implications.

Miettinen M, Kovatich AJ, Kärkkäinen P.

Virchows Arch. 1997 Dec;431(6):407-13.

PMID:
9428928
17.

Human telomerase reverse transcriptase expression in Diff-Quik-stained FNA samples from thyroid nodules.

Siddiqui MT, Greene KL, Clark DP, Xydas S, Udelsman R, Smallridge RC, Zeiger MA, Saji M.

Diagn Mol Pathol. 2001 Jun;10(2):123-9.

PMID:
11385322
18.

The utility of microscopic findings and immunohistochemistry in the classification of necrotic testicular tumors: a study of 11 cases.

Miller JS, Lee TK, Epstein JI, Ulbright TM.

Am J Surg Pathol. 2009 Sep;33(9):1293-8. doi: 10.1097/PAS.0b013e3181a3166d.

PMID:
19461507
19.

Peroxisome proliferator activated receptor gamma immunohistochemical expression in human papillary thyroid carcinoma tissues. Possible relationship to lymph node metastasis.

Galusca B, Dumollard JM, Chambonniere ML, Germain N, Prades JM, Péoc'h M, Estour B.

Anticancer Res. 2004 May-Jun;24(3b):1993-7.

20.

Use of a thin-layer technique in thyroid fine needle aspiration.

Malle D, Valeri RM, Pazaitou-Panajiotou K, Kiziridou A, Vainas I, Destouni C.

Acta Cytol. 2006 Jan-Feb;50(1):23-7.

PMID:
16514836

Supplemental Content

Support Center